

# 14

## Immunization and Infectious Diseases

Lead Agency: Centers for Disease Control and Prevention

### Contents

Goal .....	3
Overview .....	3
Issues.....	3
Trends.....	4
Disparities .....	6
Opportunities.....	7
Interim Progress Toward Year 2000 Objectives .....	8
Healthy People 2010—Summary of Objectives .....	9
Healthy People 2010 Objectives .....	11
Diseases Preventable Through Universal Vaccination.....	11
Diseases Preventable Through Targeted Vaccination .....	18
Infectious Diseases and Emerging Antimicrobial Resistance.....	23
Vaccination Coverage and Strategies .....	35
Vaccine Safety .....	48
Related Objectives From Other Focus Areas .....	49
Terminology .....	51
References .....	52



## Goal

---

Prevent disease, disability, and death from infectious diseases, including vaccine-preventable diseases.

## Overview

---

Infectious diseases remain major causes of illness, disability, and death. Moreover, new infectious agents and diseases are being detected, and some diseases considered under control have reemerged in recent years. In addition, antimicrobial resistance is evolving rapidly in a variety of hospital- and community-acquired infections. These trends suggest that many challenges still exist in the prevention and control of infectious diseases.

## Issues

Between 1980 and 1992, the number of deaths from infectious diseases rose 58 percent in the United States. Even when human immunodeficiency virus (HIV)-associated diagnoses are removed, deaths from infectious diseases still increased 22 percent during this period. (See Focus Area 13. HIV.) Considered as a group, three infectious diseases—pneumonia, influenza, and HIV infection—constituted the fifth leading cause of death in the United States in 1997.

The direct and indirect costs of infectious diseases are significant. Every hospital-acquired infection adds an average of \$2,100 to a hospital bill. Bloodstream infections result in an average of \$3,517 in additional hospital charges per infected patient because the patient stay averages an additional 7 days. A typical case of Lyme disease diagnosed in the early stages incurs about \$174 in direct medical treatment costs. Delayed diagnosis and treatment, however, can result in complications that cost from \$2,228 to \$6,724 per patient in direct medical costs in the first year alone.<sup>1</sup>

Infectious diseases also must be considered in a global context. Increases in international travel, importation of foods, inappropriate use of antibiotics on humans and animals, and environmental changes multiply the potential for worldwide epidemics of all types of infectious diseases. International cooperation and collaboration on disease surveillance, response, research, and training are essential to prevent or control these epidemics. Actions taken to improve health in one country affect the health of people worldwide.

**Vaccines.** Vaccines are biological substances that interact with the person's immune system to produce an immune response identical to that produced by the natural infection.

Vaccines can prevent the debilitating and, in some cases, fatal effects of infectious diseases. Vaccines help to eliminate the illness and disability of polio,<sup>2</sup> measles, and rubella.<sup>3</sup> However, the organisms that cause these diseases have not disappeared. Rather, they have receded and will reemerge if the vaccination coverage drops. The serious health burden of vaccine-preventable diseases (VPDs) is evident from the measles resurgence of 1989 to 1991, resulting in more than 55,000 cases, 11,000 hospitalizations, 120 deaths, and \$100 million in direct medical care costs.<sup>4, 5, 6, 7</sup>

Vaccines protect more than the vaccinated individual. They also protect society. When vaccination levels in a community are high, the few who cannot be vaccinated—such as young children and persons with contraindications to vaccination—often are indirectly protected because of group immunity (in other words, they live among vaccinated persons who may offer protection from exposure to disease).


Vaccines provide significant cost benefits. Three childhood vaccines—diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP); measles, mumps, and rubella vaccine (MMR); and *Haemophilus influenzae* type b (Hib) vaccine—result in substantial direct medical savings for each dollar spent to vaccinate children against these diseases. Varicella vaccine saves roughly 90 cents in direct medical costs for every dollar invested. Consideration of indirect savings—prevention of work loss by parents to care for ill children, prevention of death and therefore lost earnings from disability—shows that vaccines routinely recommended for children are highly cost saving. Savings range from \$24 for every dollar spent on DTaP to \$2 for the more recently approved Hib vaccine.<sup>8</sup>

## Trends

Significant progress has been made in reducing indigenous (not imported) cases of VPDs. The occurrence of many VPDs is at or near record-low levels. Most diseases have been reduced by more than 95 percent from peak prevaccine levels.<sup>9</sup>

In 1998, overall vaccination coverage for children aged 19 to 35 months was at record-high levels.<sup>10</sup> Antigen-specific rates have shown striking progress since 1992.<sup>11</sup> For example, coverage for three or more doses of polio vaccine increased from 72 percent to 91 percent, and coverage for three or more doses of Hib vaccine increased from 28 percent to 93 percent. Significant achievements also were made among racial and ethnic groups in that most of the 1996 goals for the Childhood Immunization Initiative were met for individual vaccines.<sup>12</sup> Since 1989, vaccination requirements have been expanded for schools and day care settings.<sup>11</sup> As of the 1998-99 school year, all States required vaccination against diphtheria, measles, and polio. Similarly, all States and the District of Columbia now require vaccination for day care.<sup>13</sup>

## Vaccine-Preventable Diseases: Number of Cases of Rubella, Measles, and Mumps (By year, 1980–98)



**Source:** National Notifiable Diseases Surveillance System (NNDSS), CDC, EPO, 1980–98.

In 1996, a vaccine against hepatitis A virus (HAV) was licensed that has the potential to reduce the health burden of this disease as well. The vaccine is now recommended primarily for high-risk groups. To decrease hepatitis A virus transmission, universal vaccination was recommended in 1999 for children who lived in States where the rate of new cases was greater than two times the national average.<sup>14</sup>

Financing for childhood vaccinations has improved significantly as a result of two initiatives—Vaccines for Children and the Children's Health Insurance Program that cover children on Medicaid, uninsured children, and Native American and Alaskan Native children. Underinsured children who receive vaccinations at Federal and rural health clinics also are covered. Because they promote free vaccines for children, these programs eliminate vaccine cost as a barrier to childhood vaccination. Also, the Public Health Service Act, Section 317 immunization grant program and State funds provide free vaccines for children not covered by other programs.

Adult vaccination rates continued to increase over the decade. Influenza vaccine coverage rates were up from 33 percent in 1989 to 63 percent in 1997, and pneumococcal vaccine coverage rates were up from 15 percent to 43 percent. Despite

these increases, coverage rates for certain racial and ethnic groups remain substantially below the general population.<sup>15</sup>

Invasive diseases invade the bloodstream and cause distant infection. The most common types of invasive disease caused by *Haemophilus influenzae* type b (Hib) are meningitis, epiglottitis, pneumonia, certain types of arthritis, and cellulitis. Conjugate vaccines—licensed in 1990 for use beginning at age 2 months—are highly effective in protecting against Hib meningitis and other invasive diseases caused by Hib. These vaccines also interrupt spread of the disease-causing organism by affecting the organism's nasopharyngeal colonization. New cases of Hib meningitis declined by 96 percent from 1987 to 1995.<sup>16</sup> During that period, bacterial meningitis caused by one of the five leading agents (*Haemophilus influenzae*, *Streptococcus pneumoniae*, *Neisseria meningitidis*, group B *Streptococcus* [GBS], and *Listeria monocytogenes*) fell by 55 percent. Bacterial meningitis was traditionally a disease of childhood, infecting children with a median age of 15 months in 1986.<sup>17</sup> Following the dramatic reduction in Hib meningitis, which primarily occurs among children under age 2 years, the median age of persons with the disease shifted to 25 years in 1995.<sup>17</sup> The success of conjugate vaccines against Hib disease has stimulated efforts to develop conjugate vaccines for other pathogens, including *Streptococcus pneumoniae*, *Neisseria meningitidis*, and GBS. Conjugate vaccines against these three agents are being tested in clinical trials. The success of bacterial meningitis vaccines suggests comparable results may be achieved for other causes of meningitis, sepsis, and pneumonia as their conjugate vaccines become used more routinely in target populations.

## Disparities

The updated *Preventing Emerging Infectious Diseases: A Strategy for the 21st Century* focuses on certain emerging infectious disease issues and on particular groups of people at risk.<sup>18</sup> Historically, childhood vaccination rates have been lower in certain racial and ethnic populations, compared to the white population. Vaccination rates for preschool children in racial and ethnic groups with lower vaccination rates, however, have been increasing at a more rapid rate, significantly narrowing the gap.

Efforts need to be intensified, particularly to increase vaccination coverage for children living in poverty. Substantial numbers of undervaccinated children remain in some areas, particularly the large urban areas with traditionally underserved populations, creating great concern because of the potential for outbreaks of disease.

In addition to very young children, many adults are at increased risk for VPDs. Vaccination against pneumococcal infections and influenza among persons aged 65 years and over has increased slightly for African Americans and Hispanics. The coverage in these groups, however, remains substantially below the general population. For example, influenza vaccination rates for whites were 66 percent in

1997, while for African Americans and Hispanics, rates were only 45 and 53 percent, respectively. In September 1997, the Department of Health and Human Services approved a plan to improve adult vaccination rates and reduce disparities among racial and ethnic groups.<sup>19</sup> The elimination of disparities, however, may require further interventions in particular geographic, cultural, or racial and ethnic populations.

## Opportunities

A coordinated strategy is necessary to understand, detect, control, and prevent infectious diseases. Such a strategy will protect the gains achieved in life expectancy in the 20th century resulting from control and prevention of infectious diseases and ensure further improvements in the 21st century.

Priority issues include antimicrobial resistance, foodborne and waterborne diseases, vector-borne and zoonotic diseases, diseases transmitted through transfusion of blood or blood products, and vaccine development and use. Some of these diseases and pathogens were unknown 20 years ago. Others are reemergent problems once thought under control. At-risk populations include persons with impaired host defenses; pregnant women and newborns; travelers, immigrants, and refugees; older adults; or other persons identified by the Advisory Committee on Immunization Practices (ACIP).

The major strategies to protect people from VPDs are the following:<sup>20</sup>

- Improving the quality and quantity of vaccination delivery services.
- Minimizing financial burdens for needy persons.
- Increasing community participation, education, and partnership.
- Improving monitoring of disease and vaccination coverage.
- Developing new or improved vaccines and improving vaccine use.

These strategies include a broad range of interventions for children, such as entry requirements for school and promoting the Vaccines for Children and Children's Health Insurance Program, in which eligible children are vaccinated in their medical home. Assessment of vaccination coverage of persons served at individual clinics and provider offices with feedback of the results to the individual providers to guide them in improving performance also is important. The exchange of information on coverage assessment among colleagues stimulates a friendly competition to achieve better vaccination levels.<sup>21</sup> Populations at risk of undervaccination can be reached through linkages with other programs, including Women, Infants, and Children (WIC) services.<sup>22</sup> State and local registries that enroll children and record their vaccinations are valuable tools for helping parents

and providers to identify immunization needs of individual children, assessing coverage in individual practices, and generating communitywide estimates.<sup>23</sup>

In the United States, most VPDs occur among adults. Pneumococcal disease and influenza account for more than 30,000 deaths annually, most of which occur in elderly persons. Studies have consistently shown that focusing efforts to improve coverage on health care providers, as well as health care systems, is the most effective means of raising vaccine coverage in adults. For example, all health care providers should assess routinely the vaccination status of their patients. Likewise, health plans should develop mechanisms for assessing the vaccination status of their participants. Also, nursing home facilities and hospitals should ensure that policies exist to promote vaccination.

Since no vaccine is completely safe, vaccine safety research and monitoring are necessary to identify and minimize vaccine-related injuries. As programs continue to reduce the new cases of VPDs, concerns about vaccine adverse events have emerged, posing a threat to public acceptance of vaccines. Knowing the safety profile of vaccines is essential to assess accurately the risks and benefits, to formulate appropriate vaccine recommendations, and to address public concerns.

## Interim Progress Toward Year 2000 Objectives

---

Significant progress has been made in reaching the Healthy People 2000 objectives. Reductions in indigenous cases of VPDs have been dramatic. For example, measles was reduced from a 1988 baseline of 3,396 indigenous cases to a total of only 100 in 1998. Substantial progress also has been made in reducing hepatitis B virus (HBV) transmission. The vaccine against hepatitis A provides the opportunity to reduce the burden of this disease. Achieving the year 2000 objective to reduce new cases of bacterial meningitis was entirely due to the introduction of Hib conjugate vaccines for infants.<sup>24</sup> In 1998, individual coverage levels for children aged 19 to 35 months were at record high levels. For example, individual coverage levels for three or more doses of polio, three or more doses of diphtheria/tetanus/acellular pertussis, one or more doses of measles/mumps/rubella, and three or more doses of Hib vaccines were each at or above 91 percent. Progress has also been made in expanding immunization requirements for schools and day care settings. Data for viral hepatitis indicate that targets for hepatitis B and C were met in the early 1990s.

Note: Unless otherwise noted, data are from Centers for Disease Control and Prevention, National Center for Health Statistics, *Healthy People 2000 Review, 1998-99*.

### **Immunization and Infectious Diseases**

**Goal:** Prevent disease, disability, and death from infectious diseases, including vaccine-preventable diseases.

<b>Number</b>	<b>Objective</b>
---------------	------------------

<b>Diseases Preventable Through Universal Vaccination</b>	
---	--

- |      |  |
|------|--|
| 14-1 | Vaccine-preventable diseases               |
| 14-2 | Hepatitis B in infants and young children  |
| 14-3 | Hepatitis B in adults and high-risk groups |
| 14-4 | Bacterial meningitis in young children     |
| 14-5 | Invasive pneumococcal infections           |

<b>Diseases Preventable Through Targeted Vaccination</b>	
--	--

- |      |                       |
|------|-----------------------|
| 14-6 | Hepatitis A           |
| 14-7 | Meningococcal disease |
| 14-8 | Lyme disease          |

<b>Infectious Diseases and Emerging Antimicrobial Resistance</b>	
--	--

- |       |  |
|-------|--|
| 14-9  | Hepatitis C  |
| 14-10 | Identification of persons with chronic hepatitis C                 |
| 14-11 | Tuberculosis   |
| 14-12 | Curative therapy for tuberculosis                                  |
| 14-13 | Treatment for high-risk persons with latent tuberculosis infection |
| 14-14 | Timely laboratory confirmation of tuberculosis cases               |
| 14-15 | Prevention services for international travelers                    |
| 14-16 | Invasive early-onset group B streptococcal disease                 |
| 14-17 | Peptic ulcer hospitalizations                                      |
| 14-18 | Antibiotics prescribed for ear infections                          |
| 14-19 | Antibiotics prescribed for colds                                   |
| 14-20 | Hospital-acquired infections                                       |
| 14-21 | Antimicrobial use in intensive care units                          |

### **Vaccination Coverage and Strategies**

- 14-22      Universally recommended vaccination of children aged 19 to 35 months
- 14-23      Vaccination coverage for children in day care, kindergarten, and first grade
- 14-24      Fully immunized children aged 19 to 35 months
- 14-25      Providers who measure childhood vaccination coverage levels
- 14-26      State/community population-based immunization registries for children
- 14-27      Vaccination coverage among adolescents
- 14-28      Hepatitis B vaccination among high-risk groups
- 14-29      Flu and pneumococcal vaccination of high-risk adults

### **Vaccine Safety**

- 14-30      Adverse events from vaccinations
- 14-31      Active surveillance for vaccine safety

## Diseases Preventable Through Universal Vaccination

### 14-1. Reduce or eliminate indigenous cases of vaccine-preventable disease.

Target and baseline:

Objective	Reduction in Vaccine-Preventable Diseases	1998 Baseline	2010 Target
		Number of Cases	
14-1a.	Congenital rubella syndrome	7	0
14-1b.	Diphtheria (persons under age 35 years)	1	0
14-1c.	<i>Haemophilus influenzae</i> type b* (children under age 5 years)	253	0
14-1d.	Hepatitis B (persons aged 2 to 18 years)	945 <sup>†</sup>	9
14-1e.	Measles	74	0
14-1f.	Mumps	666	0
14-1g.	Pertussis (children under age 7 years)	3,417	2,000
14-1h.	Polio (wild-type virus)	0	0
14-1i.	Rubella	364	0
14-1j.	Tetanus (persons under age 35 years)	14	0
14-1k.	Varicella (chicken pox)	4 million <sup>‡</sup>	400,000

\*Includes cases with type b and unknown serotype.

<sup>†</sup>Estimated hepatitis B cases for 1997.<sup>25</sup>

<sup>‡</sup>Data based on average from 1990-94.

**Target setting method:** Total elimination for congenital rubella syndrome, diphtheria, *Haemophilus influenzae* type b, measles, mumps, polio, rubella, and tetanus; 41 percent improvement for pertussis; 99 percent improvement for hepatitis B; and 99 percent improvement for varicella.

**Data sources:** National Notifiable Disease Surveillance System (NNDSS), CDC, EPO; National Congenital Rubella Syndrome Registry (NCRSR), CDC, NIP—congenital rubella syndrome; National Health Interview Survey (NHIS), CDC, NCHS—varicella.

Highly effective vaccines are used routinely in childhood for prevention of measles, mumps, rubella, varicella, diphtheria, tetanus, pertussis, polio, hepatitis B, and Hib invasive disease.<sup>26</sup> Vaccinations for these diseases have reduced reported cases of most VPDs common in childhood to record-low levels.<sup>10, 25, 27</sup> Measles transmission probably was interrupted multiple times in the United States since 1993.<sup>28, 29, 30</sup> With a high level of coverage of two doses of measles, mumps, and rubella vaccine, interruption of the spread of both rubella and mumps is feasible.<sup>31, 32</sup> Recent outbreaks of rubella and a number of cases of congenital rubella syndrome, however, highlight the importance of ensuring rubella immunity particularly in women of child-bearing age and foreign-born adults.<sup>33</sup> Polio has been eliminated in the United States due to high vaccination coverage. Although polio is expected to be eradicated globally, surveillance for cases of the disease will continue. Because of widespread vaccination, reported cases of diphtheria are near zero.<sup>34, 35</sup> Tetanus toxoid is highly effective, but with the absence of group immunity, all persons must be vaccinated to achieve the goal of zero cases.<sup>36</sup> Pertussis among children will be reduced by increasing vaccination coverage, but the disease will continue to occur because the organism circulates among older age groups, and the vaccine is not 100 percent effective.<sup>37, 38</sup>

Hepatitis B virus (HBV) infection will be reduced greatly as the age groups covered by universal infant and adolescent vaccination efforts enter young adulthood, a period when the risk of HBV infection increases.

Conjugate vaccines for prevention of *Haemophilus influenzae* type b are highly effective and have led to near elimination of invasive Hib disease.<sup>16, 39</sup> Further reductions in new cases are anticipated as Hib vaccine coverage increases.

The licensure of new vaccines against common diseases that are not reportable diseases, such as varicella, has created new challenges for surveillance and evaluation. Without national reporting, documenting the impact of national and State vaccination programs and measuring progress for reducing indigenous cases of disease are difficult.<sup>40</sup> However, with an increase in vaccination coverage and a decline in the number of new cases, varicella is expected to become a reportable condition.

## 14-2. Reduce chronic hepatitis B virus infections in infants and young children (perinatal infections).

**Target:** 400 infections.

**Baseline:** 1,682 chronic hepatitis B virus infections in children under age 2 years in 1995.

**Target setting method:** 76 percent improvement.

**Data source:** Perinatal Hepatitis B Prevention Program, CDC, NCID.

Each year, 16,000 to 18,000 children in the United States are born to mothers infected with HBV.<sup>41</sup> Without prevention programs, about 8,000 of these infants would become infected with HBV. Ninety-five percent of the infections, however, are preventable through appropriate maternal screening and infant care.<sup>42</sup>

Screening pregnant women during an early prenatal visit is essential to identify those who are infected. Women at high risk should be retested late in pregnancy. In 1997, 14 States had laws or regulations to ensure such screening.

To be maximally effective, steps to prevent transmission of HBV to infants born to mothers who are infected must begin as soon as the child is born. Such infants should receive a first dose of hepatitis B vaccine within 12 hours of birth, along with hepatitis B immune globulin (HBIG), and two more doses of vaccine by age 6 months. Children need to be tested between the ages of 12 and 15 months to ensure that they are not infected and have developed immunity to the virus.

## 14-3. Reduce hepatitis B.

**Target and baseline:**

Objective	Reduction in Hepatitis B	1997 Baseline	2010 Target
		Rate per 100,000	
	<b>Adults</b>		
14-3a.	19 to 24 years	24.0	2.4
14-3b.	25 to 39 years	20.2	5.1
14-3c.	40 years and older	15.0	3.8
	<b>High-risk groups</b>	Number of Cases	
14-3d.	Injection drug users	7,232	1,808
14-3e.	Heterosexually active persons	15,225	1,240
14-3f.	Men who have sex with men	7,232	1,808
14-3g.	Occupationally exposed workers	249	62

**Target setting method:** Better than the best for 14-3a, 14-3b, and 14-3c; 75 percent improvement for 14-3d, 14-3f, and 14-3g; 92 percent improvement for 14-3e.

**Data sources:** National Notifiable Disease Surveillance System (NNDSS), CDC, EPO; Sentinel Counties Study of Viral Hepatitis, CDC, NCID.

Select Age Groups, 1997	Hepatitis B Cases		
	14-3a. Aged 19 to 24 Years	14-3b. Aged 25 to 39 Years	14-3c. Aged 40 Years and Older
	Rate per 100,000		
<b>TOTAL</b>	24.0	20.2	15.0
<b>Race and ethnicity</b>			
American Indian or Alaska Native	16.0	20.1	10.9
Asian or Pacific Islander	42.2	30.4	33.2
Asian	DNC	DNC	DNC
Native Hawaiian and other Pacific Islander	DNC	DNC	DNC
Black or African American	48.3	32.5	27.6
White	10.4	10.2	7.4
Hispanic or Latino	16.9	16.0	18.1
Not Hispanic or Latino	25.2	20.7	14.8
Black or African American	50.6	34.1	28.4
White	10.3	10.2	7.1
<b>Gender</b>			
Female	24.1	15.4	9.4
Male	22.5	24.1	20.8
<b>Family income level</b>			
Poor	DNC	DNC	DNC
Near poor	DNC	DNC	DNC
Middle/high income	DNC	DNC	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

To reduce HBV transmission in the United States by 2010, vaccination programs must be targeted to adolescents and adults in high-risk groups. The primary means of achieving high levels of vaccination coverage in groups with behavioral risk factors for HBV infection is to identify settings where these individuals can be vaccinated. Such sites include clinics that treat sexually transmitted diseases, correctional facilities (juvenile detention facilities, prisons, jails), drug treatment

clinics, and community-based HIV prevention sites. The primary means of achieving high levels of vaccine coverage among household and sex contacts of the estimated 1.25 million persons in the United States with chronic HBV infection are programs that offer followup for all HbsAg-positive persons reported to State and local health departments.

Routine infant vaccination eventually will produce a highly immune population sufficient to eliminate HBV transmission in the United States. However, high rates of acute hepatitis B continue to occur, with an estimated 65,000 cases in 1996. Most cases occur in young adult risk groups, including persons with a history of multiple sex partners, men who have sex with men, injection drug users, incarcerated persons, and household and sex contacts of persons with HBV infection. Investigation of reported cases of acute hepatitis B indicates that as many as 70 percent of these individuals previously had been seen in settings such as drug treatment clinics, correctional facilities, or clinics for the treatment of STD where they could have received vaccine.

#### **14-4. Reduce bacterial meningitis in young children.**

**Target:** 8.6 new cases per 100,000 children aged 1 through 23 months.

**Baseline:** 13.0 new cases of bacterial meningitis per 100,000 children aged 1 through 23 months in 1998.

**Target setting method:** 34 percent improvement. (Better than the best will be used when data are available.)

**Data source:** Active Bacterial Core Surveillance (ABCs), CDC, NCID.

<b>Children Aged 1 Through 23 Months, 1998</b>	<b>New Cases of Bacterial Meningitis</b> Rate per 100,000
<b>TOTAL</b>	13.0
<b>Race and ethnicity</b>	
American Indian or Alaska Native	DSU
Asian or Pacific Islander	DSU
Asian	DNC
Native Hawaiian and other Pacific Islander	DNC
Black or African American	25.9
White	11.0

<b>Children Aged 1 Through 23 Months, 1998</b>	<b>New Cases of Bacterial Meningitis</b> Rate per 100,000
Hispanic or Latino	DSU
Not Hispanic or Latino	DSU
Black or African American	DSU
White	DSU
<b>Gender</b>	
Female	13.0
Male	13.1
<b>Family income level</b>	
Poor	DNC
Near poor	DNC
Middle/high income	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

Children aged 1 month to 2 years have higher rates of meningitis than older children. New vaccines for pneumococcal disease, including pneumococcal meningitis, may help protect young children. Meningococcal conjugate vaccines are in clinical trials and may become available for widespread use before 2010, although it is not yet known whether they will target young children. Pneumococcal conjugate vaccines, modeled after the successful construction of Hib conjugate vaccines, are also in clinical trials. Before 2010, licensure and widespread use of these new products are expected.

#### **14-5. Reduce invasive pneumococcal infections.**

**Target and baseline:**

Objective	Reduction in Invasive Pneumococcal Infections	1997 Baseline	2010 Target
		Rate per 100,000	
	New invasive pneumococcal infections		
14-5a.	Children under age 5 years	76	46
14-5b.	Adults aged 65 years and older	62	42
	Invasive penicillin-resistant pneumococcal infections		
14-5c.	Children under age 5 years	16	6
14-5d.	Adults aged 65 years and older	9	7

**Target setting method:** Better than the best.

**Data source:** Active Bacterial Core Surveillance (ABCs), CDC, NCID; Arctic Investigations Program (for data on pneumococcal disease rates among Alaska Natives), CDC.

Select Age Groups, 1997	New Cases of Invasive Pneumococcal Infections		New Cases of Invasive Penicillin- Resistant Pneumococcal Infections	
	14-5a. Under Age 5 Years	14-5b. Aged 65 Years and Older	14-5c. Under Age 5 Years	14-5d. Aged 65 Years and Older
	Rate per 100,000			
<b>TOTAL</b>	76	62	16	9
<b>Race and ethnicity</b>				
American Indian or Alaska Native	DSU	DSU	DSU	DSU
Asian or Pacific Islander	58	DSU	DSU	DSU
Asian	DSU	DSU	DSU	DSU
Native Hawaiian and other Pacific Islander	DSU	DSU	DSU	DSU
Black or African American	154	83	20	9
White	63	61	17	9
Hispanic or Latino	59	43	7	DSU
Not Hispanic or Latino	DSU	DSU	DSU	DSU
Black or African American	DSU	DSU	DSU	DSU
White	DNC	DNC	DNC	DNC
<b>Gender</b>				
Female	69	61	14	9
Male	84	62	17	9
<b>Family income level</b>				
Poor	DNC	DNC	DNC	DNC
Near poor	DNC	DNC	DNC	DNC
Middle/high income	DNC	DNC	DNC	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

The number of invasive penicillin-resistant pneumococcal infections can be reduced by lowering the proportion of invasive pneumococcal infections due to drug-resistant strains or by decreasing invasive pneumococcal infections in general. The objectives for specific age groups address the key age groups at risk for invasive pneumococcal infections. Among children under age 5 years, promoting judicious antibiotic use may reverse the current trends toward increasing proportions of infections being caused by drug-resistant strains. For adults aged 65 years and older, licensure and widespread use of pneumococcal conjugate vaccines by 2010 could reduce dramatically all invasive pneumococcal infections, and judicious antibiotic use may have some impact on the proportion of pneumococcal infections caused by drug-resistant strains. In this age group, a much greater impact potentially is achievable through improved use of licensed 23-valent pneumococcal polysaccharide vaccine for the prevention of invasive pneumococcal disease. Increasing the use of this vaccine for elderly persons could have a beneficial impact on the rate of drug-resistant invasive pneumococcal infections.

## Diseases Preventable Through Targeted Vaccination

### 14-6. Reduce hepatitis A.

**Target:** 4.5 new cases per 100,000 population.

**Baseline:** 11.3 new cases of hepatitis A per 100,000 population in 1997.

**Target setting method:** Better than the best.

**Data source:** National Notifiable Disease Surveillance System (NNDSS), CDC, EPO.

Total Population, 1997	New Hepatitis A Cases Rate per 100,000
<b>TOTAL</b>	11.3
<b>Race and ethnicity</b>	
American Indian or Alaska Native	23.1
Asian or Pacific Islander	4.6
Asian	DNC
Native Hawaiian and other Pacific Islander	DNC
Black or African American	6.0
White	8.1

<b>Total Population, 1997</b>	<b>New Hepatitis A Cases</b> Rate per 100,000
Hispanic or Latino	24.2
Not Hispanic or Latino	9.8
Black or African American	6.3
White	7.3
<b>Gender</b>	
Female	8.1
Male	12.8
<b>Family income level</b>	
Poor	DNC
Near poor	DNC
Middle/high income	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

The health status objectives for HAV will not be achieved until a vaccination strategy is implemented that produces high levels of immunity in children. Children have the highest rates of hepatitis A and are a primary source for new infections in the community. In 1999, the Advisory Committee on Immunization Practices (ACIP) recommended routine hepatitis A vaccination for children living in States with consistently elevated rates of hepatitis A as the approach most likely to prevent and control transmission of HAV.<sup>14</sup> Hepatitis A vaccine is included in the Vaccines for Children Program. Incorporation of hepatitis A vaccine into the routine childhood vaccination schedule would facilitate implementation of these recommendations, but data are needed to determine the appropriate dose and timing of vaccination in the first or second year of life. Implementation of the recommendations also would be enhanced by the development of vaccines that combine HAV antigen with other antigens.

Although routine immunization of children is the approach most likely to decrease significantly the overall rates of hepatitis A in a community, it may take some time before the impact of implementing these programs is measurable. In the interim, persons in groups at high risk of HAV infection should be vaccinated routinely. These groups include:

- Illicit drug users.
- Men who have sex with men.
- Persons traveling to HAV-endemic countries (see objective 14-15).

- Persons with occupational risk of infection—that is, persons who work with HAV-infected primates or with HAV in a research laboratory. No other occupational groups have been shown to be at increased risk of exposure.
- Persons with chronic liver disease.

#### 14-7. Reduce meningococcal disease.

**Target:** 1.0 new cases per 100,000 population.

**Baseline:** 1.3 new cases of meningococcal disease per 100,000 population in 1997.

**Target setting method:** Better than the best.

**Data sources:** Active Bacterial Core Surveillance (ABCs), Emerging Infection Program, CDC, NCID; National Notifiable Diseases Surveillance System (NNDSS), CDC, EPO.

Total Population, 1997	New Cases of Meningococcal Disease Rate per 100,000
<b>TOTAL</b>	1.3
<b>Race and ethnicity</b>	
American Indian or Alaska Native	DSU
Asian or Pacific Islander	DSU
Asian	DNC
Native Hawaiian and other Pacific Islander	DNC
Black or African American	1.9
White	1.2
Hispanic or Latino	DSU
Not Hispanic or Latino	DNC
Black or African American	DNC
White	DNC
<b>Gender</b>	
Female	1.2
Male	1.3

Total Population, 1997	New Cases of Meningococcal Disease Rate per 100,000
<b>Family income level</b>	
Poor	DNC
Near poor	DNC
Middle/high income	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

The polysaccharide meningococcal vaccine currently available in the United States is recommended for certain high-risk groups (people with asplenia), for laboratory personnel routinely exposed to *Neisseria meningitidis*, and for travelers to regions where meningococcal disease is hyperendemic or epidemic (the African Meningitis belt). Routine vaccination of civilians is not recommended because of its relative ineffectiveness in children under age 2 years (among whom risk of endemic disease is highest) and its relatively short duration of protection. The vaccine is useful for controlling serogroup C meningococcal epidemics; these account, however, for less than 5 percent of the cases of meningococcal disease that occur each year in the United States. The vaccine provides no protection against serogroup B meningococci, which account for approximately one-third of the disease overall in the United States.

New meningococcal conjugate vaccines against serogroups C and Y, which account for two-thirds of current disease, are now undergoing clinical trials. Soon they should be available for incorporation into routine childhood immunization as well as for vaccination of high-risk groups, possibly including college students. Similar to Hib conjugate vaccines, new meningococcal conjugate vaccines are expected to be effective in children.

Development and licensing of new serogroup B meningococcal vaccines will also help reduce meningococcal disease.

## 14-8. Reduce Lyme disease.

**Target:** 9.7 new cases per 100,000 population in endemic States.

**Baseline:** 17.4 new cases of Lyme disease per 100,000 population in 1992-96 (in endemic States of Connecticut, Delaware, Maryland, Massachusetts, Minnesota, New Jersey, New York, Pennsylvania, Rhode Island, and Wisconsin).

**Target setting method:** 44 percent improvement. (Better than the best will be used when data are available.)

**Data source:** National Notifiable Disease Surveillance System (NNDSS), CDC, EPO.

Total Population, 1992-96	New Cases of Lyme Disease Rate per 100,000
<b>TOTAL</b>	17.4
<b>Race and ethnicity</b>	
American Indian or Alaska Native	DSU
Asian or Pacific Islander	DSU
Asian	DNC
Native Hawaiian and other Pacific Islander	DSU
Black or African American	DSU
White	DSU
Hispanic or Latino	DSU
Not Hispanic or Latino	DSU
Black or African American	DSU
White	DSU
<b>Gender</b>	
Female	DNA
Male	DNA
<b>Family income level</b>	
Poor	DNC
Near poor	DNC
Middle/high income	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

In 1991 a standardized case definition for Lyme disease was adopted by the Council of State and Territorial Epidemiologists. Since then, the number of reported cases of Lyme disease has increased from 8,257 in 1993 to 16,455 in 1996

because of increased surveillance as well as a true increase in new cases. From 1992 through 1996, 92 percent of cases were reported from 10 endemic States. New initiatives to prevent Lyme disease include the implementation of community-based prevention programs, host-targeted acaricides to reduce the numbers of vector ticks, and appropriate use of Lyme disease vaccine.

## Infectious Diseases and Emerging Antimicrobial Resistance

### 14-9. Reduce hepatitis C.

**Target:** 1 new case per 100,000 population.

**Baseline:** 2.4 new cases of hepatitis C per 100,000 population in selected counties in 1996.

**Target setting method:** Better than the best.

**Data source:** Sentinel Counties Study of Viral Hepatitis, CDC, NCID.

Total Population, 1996	New Hepatitis C Cases Rate per 100,000
<b>TOTAL</b>	2.4
<b>Race and ethnicity</b>	
American Indian or Alaska Native	DNC
Asian or Pacific Islander	DSU
Asian	DNC
Native Hawaiian and other Pacific Islander	DNC
Black or African American	DSU
White	3.0
Hispanic or Latino	DSU
Not Hispanic or Latino	DSU
Black or African American	DSU
White	DSU
<b>Gender</b>	
Female	2.0
Male	2.8

Total Population, 1996	New Hepatitis C Cases Rate per 100,000
<b>Family income level</b>	
Poor	DNC
Near poor	DNC
Middle/high income	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

Note: Data represent rates based on estimates from selected counties.

Hepatitis C virus (HCV) is the most common chronic bloodborne viral infection in the United States.<sup>43</sup> This virus is usually transmitted through large or repeated percutaneous exposures to blood—for example, through sharing of equipment between injection drug users. HCV infects persons of all ages, but most new cases are among young adults aged 20 to 39 years. The highest proportion of new cases is among whites, but the highest rates of new cases are among nonwhite racial and ethnic groups.

#### **14-10. (Developmental) Increase the proportion of persons with chronic hepatitis C infection identified by State and local health departments.**

**Potential data sources:** State health department databases of persons with HCV infection; National Health and Nutrition Examination Survey (NHANES), CDC, NCHS.

An estimated 4 million persons in the United States are infected chronically with HCV. Although the annual number of newly acquired HCV infections has declined from an estimated 180,000 in the mid-1980s to an estimated 28,000 in 1995, this reservoir of chronically infected persons can transmit the virus to others, and all of them are at risk for the severe consequences of chronic liver disease. Because of the large number of people with chronic HCV infection, identification of these persons must be a major focus of a comprehensive prevention strategy. Identification of HCV-infected persons allows (1) counseling to prevent further HCV transmission, (2) vaccination against HAV and HBV to prevent additional liver damage, (3) evaluation for chronic liver disease, (4) possible antiviral therapy, and (5) counseling to avoid potential hepatotoxins, such as alcohol, that may increase the severity of HCV-related liver disease.

## 14-11. Reduce tuberculosis.

**Target:** 1.0 new case per 100,000 population.

**Baseline:** 6.8 new cases of tuberculosis per 100,000 population in 1998.

**Target setting method:** Better than the best.

**Data source:** National TB Surveillance System, CDC, NCHSTP.

Total Population, 1998	New Tuberculosis Cases Rate per 100,000
<b>TOTAL</b>	6.8
<b>Race and ethnicity</b>	
American Indian or Alaska Native	11.2
Asian or Pacific Islander	34.9
Asian	DNC
Native Hawaiian and other Pacific Islander	DNC
Black or African American	17.4
White	3.8
Hispanic or Latino	13.6
Not Hispanic or Latino	5.9
Black or African American	17.8
White	2.3
<b>Gender</b>	
Female	5.0
Male	8.6
<b>Family income level</b>	
Poor	DNC
Near poor	DNC
Middle/high income	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

The 1989 *Strategic Plan for the Elimination of TB in the United States*<sup>44</sup> set a tuberculosis elimination goal of reducing TB to 1 per million by 2010, with an interim goal of 3.5 cases per 100,000 population by 2000. However, in the mid-1980s the trend toward TB elimination was reversed, and drug-resistant strains emerged that were even more deadly. TB cases increased by 20 percent between 1985 and 1992. Renewed efforts to combat the resurgence included improving

laboratories, strengthening surveillance and expanding directly observed therapy, and expediting investigation of close contacts of TB patients. From 1993 through 1998, new cases of TB again declined, although the resurgence and related outbreaks set back TB elimination efforts by about a decade. This effort depends on significant effort and cooperation between public and private health care providers and agencies at the Federal, State, and local levels.

**14-12. Increase the proportion of all tuberculosis patients who complete curative therapy within 12 months.**

**Target:** 90 percent of patients.

**Baseline:** 74 percent of tuberculosis patients completed curative therapy within 12 months in 1996.

**Target setting method:** Better than the best.

**Data source:** National TB Surveillance System, CDC, NCHSTP.

<b>Tuberculosis Patients, 1996</b>	<b>Completed Curative Therapy Within 12 Months  Percent</b>
<b>TOTAL</b>	74
<b>Race and ethnicity</b>	
American Indian or Alaska Native	82
Asian or Pacific Islander	75
Asian	DNC
Native Hawaiian and other Pacific Islander	DNC
Black or African American	72
White	74
Hispanic or Latino	73
Not Hispanic or Latino	74
Black or African American	72
White	75
<b>Gender</b>	
Female	75
Male	73

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

**Data for socioeconomic status currently are not collected.**

The highest priority for TB control is to ensure that persons with the disease complete curative therapy. If treatment is not continued for a sufficient length of time, such persons often become ill and contagious again. Completion of therapy is essential to prevent transmission of the disease as well as to prevent outbreaks and the development and spread of drug-resistant TB.

Current therapy guidelines recommend that patients with drug-susceptible TB should complete a successful regimen within 12 months.<sup>45</sup> Multidrug-resistant TB presents difficult treatment problems, often requiring consultation with a TB specialist and longer treatment regimens. The measurement of completion of therapy is a long-accepted indicator of the effectiveness of community TB control efforts. Health departments traditionally have reported completion-of-therapy results to CDC and used this information locally and statewide as an evaluation measure.

**14-13. Increase the proportion of contacts and other high-risk persons with latent tuberculosis infection who complete a course of treatment.**

**Target:** 85 percent.

**Baseline:** 62.2 percent of tuberculosis contacts and other high-risk persons completed treatment for latent TB infection in 1997.

**Target setting method:** 27 percent improvement. (Better than the best will be used when data are available.)

**Data source:** Completion of Preventive Therapy Report forms submitted by State and local health departments, CDC, NCHSTP.

**Data for population groups currently are not collected.**

Treatment for latent TB infection substantially reduces the risk that TB infection will progress to disease. Certain groups are at very high risk of developing TB disease once infected. Identifiable population groups at high risk for TB vary in time and geographic area depending on unique and changing TB-related demographics.<sup>46</sup>

**14-14. Reduce the average time for a laboratory to confirm and report tuberculosis cases.**

**Target:** 2 days for 75 percent of cases.

**Baseline:** 21 days were needed for a laboratory to confirm and report 75 percent of TB cases in 1996.

**Target setting method:** 90 percent improvement.

**Data source:** Survey of State Public Health Laboratories, CDC, NCHSTP.

Commercially available nucleic acid amplification tests are capable of detecting *Mycobacterium tuberculosis* in a specimen within 48 hours of receipt. Concerns regarding sensitivity, cost, quality control, and special expertise requirements prevent widespread use of such tests. Upgrading TB laboratory capabilities and facilities, improving training in state-of-the-art mycobacteriology, and evaluating proficiency should better enable State public health laboratories to apply these new rapid tests to the diagnosis of TB.

**14-15. (Developmental) Increase the proportion of international travelers who receive recommended preventive services when traveling in areas of risk for select infectious diseases: hepatitis A, malaria, typhoid.**

**Potential data source:** Abstract of International Travel To and From the United States, U.S. Department of Commerce.

The number of international travelers from the United States has increased an average of 3 percent a year for the past decade. The three diseases highlighted in this objective—hepatitis A, malaria, and typhoid—account for a large proportion of illness and disability for international travelers. Before embarking, some travelers go to a travel clinic, some visit primary care providers, and some receive no pretravel care.

An appropriate prescription of antimalarial prophylaxis medications constitutes recommended preventive services for this disease. Risk areas can be identified by referencing the malaria section in the most recent edition of *Health Information for International Travel*.

**14-16. Reduce invasive early onset group B streptococcal disease.**

**Target:** 0.5 new cases per 1,000 live births.

**Baseline:** 1.0 new case of invasive early onset group B streptococcal disease per 1,000 live births in 1996.

**Target setting method:** Better than the best.

**Data source:** Active Bacterial Core Surveillance (ABCs), Emerging Infections Program Network, CDC, NCID.

<b>Live Births, 1996</b>	<b>New Cases of Group B Streptococcal Disease</b> Rate per 1,000
<b>TOTAL</b>	1.0
<b>Race and ethnicity</b>	
American Indian or Alaska Native	DSU
Asian or Pacific Islander	DSU
Asian	DNC
Native Hawaiian and other Pacific Islander	DNC
Black or African American	1.5
White	1.0
Hispanic or Latino	DSU
Not Hispanic or Latino	DSU
Black or African American	DSU
White	DSU
<b>Gender</b>	
Female	DNA
Male	DNA
<b>Family income level</b>	
Poor	DNC
Near poor	DNC
Middle/high income	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

The number of new cases of early onset group B streptococcal (GBS) disease in 1996 reflected a substantial decline from earlier years, before intervention became common practice. GBS causes bloodstream infections and meningitis in babies. Additional prevention is possible, since occurrence of the disease is more likely to reflect ineffective prevention efforts than antibiotic failures. In certain areas, rates approximating 0.5 per 1,000 births already have been achieved. Although these data may represent the background rate of nonpreventable cases, most geographic areas should be able to achieve the same low rates. The racial disparity in rates will be eliminated with more aggressive use of prevention protocols.

African Americans have consistently had higher rates of GBS diseases than other races. Implementation of GBS prevention policies is expected to eliminate the disparity. Thus, the target of 0.5 cases per 1,000 births is one that can be obtained

in all geographic areas and all racial and ethnic groups. By the year 2010, reductions in early-onset disease might be the result of both improved use of intrapartum antibiotic prophylaxis and implementation of GBS conjugate vaccines currently in clinical trials.

#### **14-17. Reduce hospitalizations caused by peptic ulcer disease in the United States.**

**Target:** 46 hospitalizations per 100,000 population.

**Baseline:** 71 hospitalizations per 100,000 population in 1997.

**Target setting method:** Better than the best.

**Data source:** National Hospital Discharge Survey (NHDS), CDC, NCHS.

<b>Total Population, 1997</b>	<b>Peptic Ulcer Hospitalizations Rate per 100,000</b>
<b>TOTAL</b>	71
<b>Race and ethnicity</b>	
American Indian or Alaska Native	DSU
Asian or Pacific Islander	DSU
Asian	DNC
Native Hawaiian and other Pacific Islander	DNC
Black or African American	79
White	53
Hispanic or Latino	DSU
Not Hispanic or Latino	DSU
Black or African American	DSU
White	DSU
<b>Gender</b>	
Female	65
Male	78
<b>Family income level</b>	
Poor	DNC
Near poor	DNC
Middle/high income	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

Note: Age adjusted to the year 2000 standard population.

Peptic ulcer disease affects up to 25 million persons in the United States and causes up to 6,500 deaths each year. Until recently, peptic ulcers were thought to be caused by stress, spicy foods, and excess stomach acid. Most patients were treated with antacids or acid-reducing medications, and recurrences were the rule after therapy was discontinued. The discovery in the 1980s that a bacterial organism, *Helicobacter pylori* (*H. pylori*), causes up to 90 percent of peptic ulcers has changed the way ulcers are evaluated and managed.<sup>47, 48</sup> Now appropriate antibiotic regimens successfully eradicate the infection and prevent recurrence and complications such as bleeding or perforation.

Despite extensive scientific data linking peptic ulcer disease to *H. pylori*, studies indicate that many health care providers and consumers are unaware of the relationship, and many persons with ulcers do not receive appropriate therapy.<sup>49, 50</sup> A campaign to educate health care providers and consumers about *H. pylori* and its link to peptic ulcer disease was initiated in 1997. The CDC and Partnership H. pylori Educational Campaign includes partners from academic institutions, government agencies, and industry.<sup>51</sup> The increased awareness of the link between *H. pylori* and ulcers among health care providers and consumers is expected to lead to the increased use of appropriate antibiotics. This improved treatment, if available to those who need it, should decrease hospitalization rates—an indicator for severe illness and disability—due to peptic ulcer disease and its complications.

#### **14-18. Reduce the number of courses of antibiotics for ear infections for young children.**

**Target:** 88 antibiotic courses per 100 children under age 5 years.

**Baseline:** 108 antibiotic courses for otitis media per 100 children under age 5 years were prescribed during 1996-97 (2-year average).

**Target setting method:** 19 percent improvement.

**Data sources:** National Ambulatory Medical Care Survey (NAMCS), CDC, NCHS; National Hospital Ambulatory Medical Care Survey (NHAMCS), CDC, NCHS.

<b>Children Under Age 5 Years, 1996-97</b>	<b>Courses of Antibiotics for Ear Infections</b> Rate per 100
<b>TOTAL</b>	108
<b>Race and ethnicity</b>	
American Indian or Alaska Native	DSU
Asian or Pacific Islander	DSU
Asian	DNC
Native Hawaiian and other Pacific Islander	DNC
Black or African American	84
White	116
Hispanic or Latino	DSU
Not Hispanic or Latino	DSU
Black or African American	DSU
White	DSU
<b>Gender</b>	
Female	107
Male	109

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

**Data for socioeconomic status currently are not collected.**

Antibiotic courses for otitis media, commonly called ear infection, can be reduced through two methods. A portion of otitis media cases—otitis media with effusion, rather than acute otitis media—do not require antimicrobial treatment. A national campaign for judicious antibiotic use aims to reduce inappropriate antibiotic treatment for this portion of otitis media.<sup>52</sup> The leading cause of otitis media is pneumococcus. Preventing pneumococcal otitis media is expected to be possible following licensure of pneumococcal conjugate vaccines. (See Focus Area 28. Vision and Hearing.)

**14-19. Reduce the number of courses of antibiotics prescribed for the sole diagnosis of the common cold.**

**Target:** 1,268 antibiotic courses per 100,000 population.

**Baseline:** 2,535 antibiotic courses per 100,000 population were prescribed for the sole diagnosis of the common cold, 1996-97.

**Target setting method:** 50 percent improvement.

**Data sources:** National Ambulatory Medical Care Survey (NAMCS), CDC, NCHS; National Hospital Ambulatory Medical Care Survey (NHAMCS), CDC, NCHS.

<b>Total Population, 1996-97</b>	<b>Courses of Antibiotics for Common Cold</b> Rate per 100,000
<b>TOTAL</b>	2,535
<b>Race and ethnicity</b>	
American Indian or Alaska Native	DSU
Asian or Pacific Islander	DSU
Asian	DNC
Native Hawaiian and other Pacific Islander	DNC
Black or African American	DSU
White	2,431
Hispanic or Latino	DSU
Not Hispanic or Latino	DSU
Black or African American	DSU
White	DSU
<b>Gender</b>	
Female	2,644
Male	2,421
<b>Family income level</b>	
Poor	DNC
Near poor	DNC
Middle/high income	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

The common cold does not require antimicrobial therapy. Inappropriate therapy for the common cold can be reduced by 50 percent by promoting judicious antimicrobial use, provided that care givers and patients accept that antibiotics are ineffective in treating colds. Effective programs for the judicious use of antibiotics could help reduce the prescription of antibiotics for the common cold.

## 14-20. Reduce hospital-acquired infections in intensive care unit patients.

Target and baseline:

Objective	Reduction in Hospital-Acquired Infections in Intensive Care Units	1998 Baseline Infections per 1,000 Days' Use	2010 Target
<b>Intensive care patients</b>			
14-20a.	Catheter-associated urinary tract infection	5.9	5.3
14-20b.	Central line-associated blood-stream infection	5.3	4.8
14-20c.	Ventilator-associated pneumonia	11.1	10.0
<b>Infants weighing 1,000 grams or less in intensive care</b>			
14-20d.	Central line-associated blood-stream infection	12.2	11.0
14-20e.	Ventilator-associated pneumonia	4.9	4.4

**Target setting method:** 10 percent improvement. (Better than the best will be used when data are available.)

**Data source:** National Nosocomial Infections Surveillance System (NNIS), CDC, NCID.

**Data for population groups currently are not collected.**

Hospital-acquired infections are a leading cause of illness and death in the United States. Each year, 36 million patients are admitted to U.S. hospitals. Annually, more than 500,000 of the nearly 2 million patients stricken with a hospital-acquired infection are intensive care patients. Of the total, nearly 90,000 die. The annual cost of hospital-acquired infections is approximately \$4.5 billion a year. In the last 20 years, the rate of hospital-acquired infections has increased 36 percent.

The rate of hospital-acquired infections has increased largely because hospital patients of the late 1990s on average were older and sicker than those of 20 years earlier and thus more susceptible to infection, and also because medical advances that can save or prolong lives may carry risks for infections. Because both trends are expected to continue, only a modest reduction in the number of new cases of infections can be expected; however, a small reduction will save thousands of lives.

## 14-21. Reduce antimicrobial use among intensive care unit patients.

**Target:** 120 daily doses per 1,000 patient days.

**Baseline:** 150 daily doses of antimicrobials per 1,000 patient days were used among intensive care unit patients in 1995.

**Target setting method:** 20 percent improvement.

**Data source:** National Nosocomial Infections Surveillance System (NNIS), CDC, NCID.

Hospital-acquired infections caused by antimicrobial-resistant pathogens can be virtually untreatable. Further, antimicrobial resistance that develops in the hospital can spread into the community and has the potential to cause a public health disaster. Excessive or inappropriate use of antimicrobials or both, which occur most frequently in intensive care units (ICUs), is the major cause of antimicrobial resistance. Research indicates that antibiotics are being used more often than hospital prescription guidelines recommend. For example, one study in the late 1990s indicated that as much as 60 percent of the hospital prescriptions for vancomycin are not in accordance with the guidelines. Decreasing the use of antimicrobials, especially in intensive care units, is the critical step in reducing the public threat of antimicrobial resistance. Studies have shown that interventions in individual hospitals have achieved reductions of 20 percent or more in antimicrobial use.

## Vaccination Coverage and Strategies

### 14-22. Achieve and maintain effective vaccination coverage levels for universally recommended vaccines among young children.

**Target and baseline:**

Objective	Increase and Maintenance of Vaccination Coverage Levels Among Children Aged 19 Through 35 Months	1998 Baseline	2010 Target
		Percent	
14-22a.	4 doses diphtheria-tetanus-pertussis (DtaP) vaccine	84	90
14-22b.	3 doses <i>Haemophilus influenzae</i> type b (Hib) vaccine	93	90
14-22c.	3 doses hepatitis B vaccine (hep B)	87	90
14-22d.	1 dose measles-mumps-rubella (MMR) vaccine	92	90
14-22e.	3 doses polio vaccine	91	90
14-22f.	1 dose varicella vaccine	43	90

**Target setting method:** Consistent with the Childhood Immunization Initiative.

**Data source:** National Immunization Survey (NIS), CDC, NCHS and NIP.

Children Aged 19 Through 35 Months, 1998	Vaccination Coverage					
	14-22a. 4 Doses DTaP	14-22b 3 Doses Hib	14-22c. 3 Doses Hep B	14-22d. 1 Dose MMR	14-22e. 3 Doses Polio	14-22f. 1 Dose Varicella
	Percent					
<b>TOTAL</b>	84	93	87	92	91	43
<b>Race and ethnicity</b>						
American Indian or Alaska Native	78	92	80	86	83	33
Asian or Pacific Islander	87	93	90	93	94	57
Asian	DNC	DNC	DNC	DNC	DNC	DNC
Native Hawaiian and other Pacific Islander	DNC	DNC	DNC	DNC	DNC	DNC
Black or African American	77	90	84	89	88	43
White	86	94	88	93	92	43
Hispanic or Latino	80	92	86	91	89	47
Not Hispanic or Latino	85	94	87	92	91	42
Black or African American	77	90	84	89	88	42
White	87	95	88	93	92	42
<b>Gender</b>						
Female	84	94	87	92	91	43
Male	84	93	87	92	90	43
<b>Family income level</b>						
Poor	81	92	86	91	90	46
Near poor	83	92	87	91	91	42
Middle/high income	89	96	89	94	92	49

Children Aged 19 Through 35 Months, 1998	Vaccination Coverage					
	14-22a. 4 Doses DTaP	14-22b 3 Doses Hib	14-22c. 3 Doses Hep B	14-22d. 1 Dose MMR	14-22e. 3 Doses Polio	14-22f. 1 Dose Varicella
	Percent					
Disability status						
Persons with disabilities	DNC	DNC	DNC	DNC	DNC	DNC
Persons without disabilities	DNC	DNC	DNC	DNC	DNC	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

Vaccination coverage levels of 90 percent are, in general, sufficient to prevent circulation of viruses and bacteria causing vaccine-preventable diseases.<sup>53, 54</sup> Maintenance of high vaccination coverage levels in early childhood is the best way to prevent the spread of VPDs in childhood and to provide the foundation for controlling VPDs among adults. Diseases that affect humans only may eventually be eradicated or at least eliminated through high vaccination coverage levels.<sup>55</sup> These diseases include polio and measles in the near future and possibly hepatitis B later on. Although polio is expected to be eradicated by the year 2000, vaccine coverage levels will continue to be assessed until vaccination is no longer recommended. The measles epidemic of 1989-91 demonstrated that achievement of high coverage levels at the time of school entry was insufficient to control VPD outbreaks. Although coverage levels are currently the highest ever recorded, the United States must continue to assure that each new cohort of children is fully vaccinated with all required vaccine doses; as of November 1, 1999, 16 to 20 vaccine doses are required through age 16 years with 12 to 16 doses by age 2 years. Any new universally recommended vaccine should be at a 90 percent coverage level within 5 years of the recommendation.

Although national coverage levels may exceed 90 percent, variation in the level of coverage among smaller areas may include subgroups of the population at substantially lower levels of protection. These subgroups or pockets of undervaccinated persons make the population vulnerable to major outbreaks of VPDs. Monitoring of coverage at smaller geographic levels within the United States helps ensure that these potential pockets of children are identified to target interventions and reduce the risk of future disease outbreaks. In addition, each State and major urban area should aim to achieve 90 percent coverage to ensure uniformly high vaccination coverage.

**14-23. Maintain vaccination coverage levels for children in licensed day care facilities and children in kindergarten through the first grade.**

**Target and baseline:**

Objective	Maintain Vaccination Coverage Levels for Children	1997–98 Baseline	2010 Target
		Percent	
	<b>Children in day care</b>		
14-23a.	Diphtheria-tetanus-acellular pertussis (DTaP) vaccine	96	95
14-23b.	Measles-mumps-rubella (MMR) vaccine	93	95
14-23c.	Polio vaccine	95	95
14-23d.	Hepatitis B vaccine	<b>Developmental</b>	
14-23e.	Varicella vaccine	<b>Developmental</b>	
	<b>Children in K-1st grade</b>		
14-23f.	Diphtheria-tetanus-acellular pertussis (DtaP) vaccine	97	95
14-23g.	Measles-mumps-rubella (MMR) vaccine	96	95
14-23h.	Polio vaccine	97	95
14-23i.	Hepatitis B vaccine	<b>Developmental</b>	
14-23j.	Varicella vaccine	<b>Developmental</b>	

**Target setting method:** Consistent with year 2000 target. (Better than the best will be used when data are available.)

**Data source:** Immunization Program Annual Reports, CDC, NIP.

<b>Data for population groups currently are not collected.</b>
--

Uniformly high coverage levels are required to prevent circulation of the viruses and bacteria that cause VPDs. The target level was set to be consistent with the Healthy People 2000 objective because the achievement of that objective has been successful at preventing disease spread, and this objective seeks to maintain the high coverage achieved in these settings.

Entry requirements for school and day care are one of the most effective interventions the States have at their disposal to ensure that children are appropriately vaccinated. The impact of entry requirements for school and day care has been profound—more than 95 percent of children are vaccinated. Several studies support the role of entry requirements in increasing vaccination rates and decreasing the rate of new cases of measles. Strict enforcement of school vaccination re-

quirements has been shown to play a determining role in lowering new cases of measles.<sup>56</sup>

**14-24. Increase the proportion of young children who receive all vaccines that have been recommended for universal administration for at least 5 years.**

**Target:** 80 percent of children aged 19 through 35 months.

**Baseline:** 73 percent of children aged 19 through 35 months received the recommended vaccines (4 DTaP, 3 polio, 1 MMR, 3 Hib, 3 hepatitis B) in 1998.

**Target setting method:** Better than the best.

**Data source:** National Immunization Survey (NIS), CDC, NCHS and NIP.

Children Aged 19 Through 35 Months, 1998	Vaccinations	
	14-24. 4 DTaP, 3 polio, 1 MMR, 3 Hib, 3 Hepatitis B	4 DTaP, 3 polio, 1 MMR*
	Percent	
<b>TOTAL</b>	73	81
<b>Race and ethnicity</b>		
American Indian or Alaska Native	65	75
Asian or Pacific Islander	73	82
Asian	DNC	DNC
Native Hawaiian and other Pacific Islander	DNC	DNC
Black or African American	66	74
White	74	82
Hispanic or Latino	69	77
Not Hispanic or Latino	74	81
Black or African American	67	74
White	76	83
<b>Gender</b>		
Female	72	81
Male	73	81

Children Aged 19 Through 35 Months, 1998	Vaccinations	
	14-24. 4 DTaP, 3 polio, 1 MMR, 3 Hib, 3 Hepatitis B	4 DTaP, 3 polio, 1 MMR*
	Percent	
Family income level		
Poor	70	78
Near poor	72	80
Middle/high income	77	85
Disability status		
Persons with disabilities	DNC	DNC
Persons without disabilities	DNC	DNC

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

\*Data for 4 DTaP, 3 polio, and 1 MMR are displayed to further characterize the issue.

Determining whether the population is protected against a VPD is best evaluated by examining the immunization coverage of individual vaccines (see objective 14-22). It is also important to assure that the health care system fully vaccinates individual children, providing vaccines that have been universally recommended for at least 5 years and that are currently recommended. Changes in the immunization schedule will occur as new vaccines are added to the list of recommended vaccines and as vaccines for eradicated diseases are removed from the list.<sup>57</sup> For example, polio virus vaccine is not expected to be recommended by the year 2010. Although monitoring the proportion of children who have received the combination of four DTaP, three polio, and one MMR will continue for historical comparison, attention should be focused on the combination of all universally recommended vaccines.

#### **14-25. Increase the proportion of providers who have measured the vaccination coverage levels among children in their practice population within the past 2 years.**

**Target and baseline:**

Objective	Increase in Providers Measuring Vaccination Levels	1997 Baseline	2010 Target
		Percent	
<b>14-25a.</b>	Public health providers	66	90
<b>14-25b.</b>	Private providers	6	90

**Target setting method:** 36 percent improvement for public health providers; 1,400 percent improvement for private providers.

**Data source:** Immunization Program Annual Reports, CDC, NIP.

In 1997, 66 percent of public health department providers assessed their vaccination levels.<sup>58</sup> State immunization programs are collaborating with private providers to extend provider-based assessments to the private sector. With the increasing role of managed care and Health Plan and Employer Data and Information Set (HEDIS) measures, private providers should have additional occasions to examine their coverage levels.

Most providers (public and private) overestimate the vaccination coverage level they are achieving with their clients.<sup>59</sup> Assessment of practice-based coverage levels and feedback of those data to the providers have been an effective strategy for increasing vaccination of children served by a given practice.<sup>60, 61</sup> Managed care organizations have begun reporting vaccination coverage levels using the HEDIS criteria as a way of evaluating quality of care.<sup>62</sup> Practice-based assessment also has been recommended by the Advisory Committee on Immunization Practices,<sup>63</sup> the National Vaccine Advisory Committee, the American Academy of Pediatrics, and the American Academy of Family Physicians.<sup>64</sup> The Clinic Assessment Software Application provides a mechanism for assessing levels of vaccination coverage as well as for tracking patients; the system reminds patients of upcoming vaccinations and sends notices for children who are overdue.

#### **14-26. Increase the proportion of children who participate in fully operational population-based immunization registries.**

**Target:** 95 percent of children under age 6 years.

**Baseline:** 32 percent of children under age 6 years participated in a fully operational population-based immunization registry in 1998.

**Target setting method:** 197 percent improvement. (Better than the best will be used when data are available.)

**Data source:** Immunization Program Annual Reports, CDC, NIP.

<b>Data for population groups currently are not collected.</b>
--

A fully operational population-based registry includes capabilities to (1) protect confidential information, (2) enroll all children at the State or community level automatically at birth, (3) give providers access to complete vaccination history, (4) recommend needed vaccinations, (5) notify children who are due and overdue for vaccinations, (6) assess practice and geographic-level coverage, and (7) produce authorized immunization records. Registries may provide other important functions such as automatic reporting of adverse events. Registries may serve

other purposes as well, including VPD surveillance, vaccine efficacy monitoring, and vaccine inventory management.

Population-based immunization registries will be a cornerstone of the Nation=s immunization system by 2010. Responsibility for registry development rests with State and local communities, with assistance from Federal agencies and private partners. Registries facilitate the timely vaccination of children by ensuring that the child=s complete vaccination history is available to the health care provider. Registries are valuable given the mobile nature of today=s population and that many persons do not see the same provider consistently. Registries also can be used to monitor the vaccination status of populations that are low income, uninsured, and at greater risk for incomplete vaccination.

Few population-based immunization registries existed at the State or community level before 1992, and limited data are available regarding their implementation. A 1999 CDC survey shows immunization registries are being developed in all States.<sup>65</sup> Additional efforts are underway to establish registry links between private providers and immunization partners such as managed care organizations and WIC programs. Issues such as privacy, confidentiality, and access of registry data are being addressed as registries are developed.

Participation in immunization registries will continue to increase. The development of childhood immunization registries has widespread support among parents and providers<sup>66</sup> and the required technology is becoming less expensive and simpler. Registries are part of the current trend to computerize medical data in the United States. To be successful, registries must be seamlessly integrated into the current provider environment and create no additional burdens.

#### **14-27. (Developmental) Increase routine vaccination coverage levels of adolescents.**

**Potential data source:** National Health Interview Survey (NHIS), CDC, NCHS.

Illness and disability caused by vaccine-preventable diseases, such as hepatitis B, measles, and varicella, continue among adolescents.<sup>25</sup> While primary health care providers are vital to ensuring that infants and younger children are up to date on their vaccinations, they have an equally important role in ensuring comprehensive vaccination for adolescents.<sup>67</sup> Any new universally recommended vaccine for adolescents should be at a 90 percent coverage level within 5 years of the recommendation. An estimated 79 percent of adolescents and children visit a health care provider annually.<sup>68</sup> Providers such as nurses, nurse practitioners, pediatricians, family physicians, general practitioners, and emergency medicine specialists deliver most of the primary health care received by adolescents.<sup>69</sup> Strategies should specifically target these providers to increase vaccination among adolescents, especially hard-to-reach and at-risk adolescents in urban and rural areas.

School entry laws and regulations ensure high vaccination levels. Much of the experience to date in implementing adolescent vaccination comes from school-based hepatitis B demonstration projects.<sup>70</sup> To encourage school participation in an adolescent vaccination program, a partnership between schools and local health departments is essential.

Managed care organizations also have an increasingly important role in the delivery of health care services, including vaccinations, to adolescents. Measures for assessing immunization recommendations for adolescents have been incorporated into HEDIS 3.0.<sup>62</sup> Such standards should greatly assist in implementing immunization recommendations for adolescents in the managed care setting.

#### **14-28. Increase hepatitis B vaccine coverage among high-risk groups.**

**Target and baseline:**

Objective	Increase Hepatitis B Vaccine Coverage in High-Risk Groups	1995 Baseline	2010 Target
		Percent	
<b>14-28a.</b>	Long-term hemodialysis patients	35	90
<b>14-28b.</b>	Men who have sex with men	9	60
<b>14-28c.</b>	Occupationally exposed workers	71	98

**Target setting method:** 157 percent improvement for long-term hemodialysis patients; 567 percent improvement for men who have sex with men; 38 percent improvement for occupationally exposed workers.

**Data sources:** Young Men=s Survey, CDC, NCHSTP; Annual Survey of Chronic Hemodialysis Centers, CDC, NCID, and HCFA; Periodic vaccine coverage surveys, CDC, NCID.

Hepatitis B vaccination has been recommended for persons with risk factors for hepatitis B virus infection since the vaccine was first licensed in 1981. These risk groups include the following: hemodialysis patients, men who have sex with men, incarcerated persons, health care and public safety workers who have exposure to blood in the workplace, persons with a history of sexually transmitted diseases or multiple sex partners, injection drug users, and household and sex contacts of HBV-infected persons. While data currently are not collected for inmates in long-term correctional facilities, it is recommended that prison officials should consider undertaking screening and vaccination programs directed at inmates with histories of high-risk behaviors.

**14-29. Increase the proportion of adults who are vaccinated annually against influenza and ever vaccinated against pneumococcal disease.**

**Target and baseline:**

Objective	Increase in Adult Vaccinations	1997 Baseline	2010 Target
		Percent	
	<b>Noninstitutionalized adults aged 65 years and older*</b>		
<b>14-29a.</b>	Influenza vaccine	63	90
<b>14-29b.</b>	Pneumococcal vaccine	43	90
	<b>Noninstitutionalized high-risk adults aged 18 to 64 years *</b>		
<b>14-29c.</b>	Influenza vaccine	25	60
<b>14-29d.</b>	Pneumococcal vaccine	11	60
	<b>Institutionalized adults (persons in long-term or nursing homes)<sup>†</sup></b>		
<b>14-29e.</b>	Influenza vaccine	64	90
<b>14-29f.</b>	Pneumococcal vaccine	28	90

\*Data on noninstitutionalized population age adjusted to the year 2000 standard population.

<sup>†</sup>Data on institutionalized population age adjusted to the year 2000 nursing home population. National Nursing Home Survey estimates include a significant number of residents who have an unknown vaccination status. See *Tracking Healthy People 2010* for further discussion of the data issues.

**Target setting method:** Better than the best.

**Data sources:** National Health Interview Survey (NHIS), CDC, NCHS—noninstitutionalized populations; National Nursing Home Survey (NNHS), CDC, NCHS—institutionalized populations.

Select Age Groups, 1997	Annual Influenza and One-Time Pneumococcal Vaccinations					
	Noninstitutional- ized Adults Aged 65 Years and Older*		Noninstitutional- ized High-Risk Adults Aged 18 to 64 Years*		Institutionalized Adults Aged 18 Years and Older†	
	14-29a. Influenza	14-29b. Pneumo- coccal Disease	14-29c. Influenza	14-29d. Pneumo- coccal Disease	14-29e. Influenza	14-29f. Pneu- moco- cal Disease
	Percent					
<b>TOTAL</b>	63	43	25	11	64	28
<b>Race and ethnicity</b>						
American Indian/ Alaska Native	DSU	DSU	29	22	DSU	DSU
Asian or Pacific Is- lander	50	24	22	DSU	DSU	DSU
Asian	50	DSU	DSU	DSU	DNC	DNC
Native Hawaiian and other Pacific Islander	DSU	DSU	DSU	DSU	DNC	DNC
Black or African American	45	22	21	13	DNA	DNA
White	65	45	25	11	DNA	DNA
Hispanic or Latino	53	24	18	7	52	17
Not Hispanic or Latino	64	44	25	11	DNA	DNA
Black or African American	45	22	21	13	60	24
White	66	46	26	11	65	29
<b>Gender</b>						
Female	62	42	26	11	DNA	DNA
Male	65	44	23	11	DNA	DNA
<b>Education level</b>						
Less than high school	58	37	18	10	DNA	DNA
High school graduate	65	45	24	12	DNA	DNA
Some college	69	48	27	11	DNA	DNA

Select Age Groups, 1997	Annual Influenza and One-Time Pneumococcal Vaccinations					
	Noninstitutional- ized Adults Aged 65 Years and Older*		Noninstitutional- ized High-Risk Adults Aged 18 to 64 Years*		Institutionalized Adults Aged 18 Years and Older†	
	14-29a. Influenza	14-29b. Pneumo- coccal Disease	14-29c. Influenza	14-29d. Pneumo- coccal Disease	14-29e. Influenza	14-29f. Pneumo- coccal Disease
	Percent					
Disability status						
Persons with disabilities	66	47	28	16	DNA	DNA
Persons without disabilities	62	40	23	9	DNA	DNA
Select populations						
Age Groups						
18 to 49 years	NA	NA	19	8	59	26
50 to 64 years	NA	NA	40	19	62	23
65 to 74 years	61	40	NA	NA	62	28
75 to 84 years	66	46	NA	NA	61	26
85 years and older	67	42	NA	NA	66	30
Persons with diabetes	68	44	27	15	DNA	DNA
Persons with heart disease	71	51	25	11	DNA	DNA
Persons with lung disease	73	65	25	13	DNA	DNA
Persons with lung disease (excluding asthma)	74	66	26	14	DNA	DNA
Persons with kidney disease	71	46	21	13	DNA	DNA
Persons with liver disease	71	43	26	10	DNA	DNA
Persons with cancer	71	51	25	10	DNA	DNA

DNA = Data have not been analyzed. DNC = Data are not collected. DSU = Data are statistically unreliable.

\*Data on noninstitutionalized population age adjusted to the year 2000 standard population.

†Data on institutionalized population age adjusted to the year 2000 nursing home population.

Federal initiatives have highlighted the need to focus vaccination resources on adults.<sup>71</sup> Vaccination is an effective strategy to reduce illness and deaths due to pneumococcal disease and influenza. Current levels of coverage among adults vary widely among age, risk, and racial and ethnic groups. Any new universally recommended vaccine should be at a 60 percent coverage level within 5 years of recommendation. Influenza and pneumococcal vaccines are covered by Medicare; thus vaccinating greater numbers of adults aged 65 years and older is feasible. High-risk adults aged 18 to 64 years may not have insurance coverage for influenza and pneumococcal vaccines.

With the aging of the U.S. population, increasing numbers of adults will be at risk for these major causes of illness and death. Persons with high-risk conditions (that is, heart disease, diabetes, and chronic respiratory disease<sup>72, 73</sup>) remain at increased risk for these diseases, as do persons living in institutional settings.

Continuing education of providers and the community is needed to increase awareness of and demand for adult vaccination services. Interventions, such as standing orders for vaccination, provider reminders and feedback, and patient notifications and reminders have been effective in increasing adult vaccination levels.<sup>21, 74</sup> Guidelines and tools for implementing these interventions are available through *Put Prevention Into Practice*, a national campaign to improve delivery of clinical preventive services.<sup>75</sup> Measurement and feedback about vaccination providers= performance in delivering vaccines enhance coverage rates. Providers should be given feedback on their performance in a timely manner. Measurement and feedback can result in improvements in vaccine coverage either by changing provider knowledge, attitudes, and behavior or by stimulating changes in the vaccine delivery system—for example, reminders and standing orders—or some combination.

In addition, opportunities for vaccination outside of primary care and other traditional health care settings could be increased to reach elderly persons who do not routinely access primary care. For example, over 90 million emergency department visits are made in the United States annually. Emergency department vaccination is likely to increase vaccination rates among select populations difficult to vaccinate through office-based programs. In any nontraditional site, a method for tracking and communicating vaccinations is needed so that vaccination information may be shared with patients= primary care providers.

## Vaccine Safety

### 14-30. Reduce vaccine-associated adverse events.

**14-30a.** Eliminate vaccine-associated paralytic polio (VAPP).

**Target:** Zero cases.

**Baseline:** 5 VAPP cases in 1997.

**Target setting method:** Total elimination.

**Data source:** National Notifiable Disease Surveillance System (NNDSS), CDC, EPO.

**14-30b.** Reduce febrile seizures caused by pertussis vaccines.

**Target:** 75 febrile seizures.

**Baseline:** 152 febrile seizures were caused by pertussis vaccines in 1998.

**Target setting method:** 50 percent improvement.

**Data sources:** Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD), CDC, NIP.

Because no natural reservoirs for wild poliomyelitis exist, VAPP is caused by the oral polio vaccine (OPV). With global polio eradication targeted for 2000, use of OPV should decrease and then stop, resulting in zero cases of VAPP. From 1980 to 1998, no indigenous cases of paralytic poliomyelitis caused by wild polio virus transmission have occurred in the United States. However, 141 cases of VAPP have been reported in this same period, averaging 8 or 9 cases per year. Persons with VAPP experience the full range of illness and disability as well as loss of social function associated with being partially or fully paralyzed. Due to the progress in global poliomyelitis eradication and to the reduction of the burden of VAPP in the United States, ACIP recommended that beginning in 2000, only IPV will be used for routine immunization.<sup>76</sup> In general, IPV is as effective as OPV and should be sufficient at preventing polio in the United States.

Controlled clinical trials indicate that whole cell pertussis (wP) vaccines cause seizures at a frequency of 1 per 1,750 doses.<sup>37, 77, 78</sup> The majority of these seizures are febrile seizures without any residual deficit. Nevertheless, such seizures—frightening patients and parents alike—frequently result in emergency department or other medical visits as well as costly diagnostic evaluations to rule out possible neurologic disorders. Recently licensed acellular pertussis (aP) vaccines are less likely to cause fever or seizures; data show seizure frequency of up to 1 per 14,280 doses.<sup>37</sup> With the increasing use of aP vaccines, the number of pertussis vaccine-associated febrile seizures should be reduced by 50 percent.

## **14-31. Increase the number of persons under active surveillance for vaccine safety via large linked databases.**

**Target:** 13 million persons.

**Baseline:** 6 million persons were under active surveillance for vaccine safety via large linked databases in 1999.

**Target setting method:** 117 percent improvement.

**Data source:** Vaccine-Safety Datalink, CDC, NIP.

A high standard of safety is expected of vaccines since they are recommended for millions of healthy people, including infants. Vaccine safety monitoring to identify and minimize vaccine-related reactions is necessary to help ensure safety because no vaccine is completely safe. Knowledge of vaccine safety is essential to accurately assess the risks and benefits in formulating vaccine use recommendations. For example, the Institute of Medicine has reported that of 76 adverse events assessed, 66 percent had inadequate or no evidence available to accept or reject vaccine as a cause of the adverse reactions.<sup>79, 80</sup>

In collaboration with several health maintenance organizations, CDC has linked anonymous vaccination and medical records in a large database.<sup>81</sup> This system is used to study vaccine safety, especially for evaluating new concerns arising from the Vaccine Adverse Event reporting System (VAERS) and other sources. These databases also are used for monitoring vaccine safety, conducting active surveillance of VPDs, carrying out vaccine safety and immunogenicity trials, evaluating vaccine economics, and assessing vaccine coverage.

## **Related Objectives From Other Focus Areas**

---

### **1. Access to Quality Health Services**

- 1-1. Persons with health insurance
- 1-2. Health insurance coverage for clinical preventive services
- 1-3. Counseling about health behaviors
- 1-4. Source of ongoing care
- 1-5. Usual primary care provider
- 1-6. Difficulties or delays in obtaining needed health care
- 1-7. Core competencies in health provider training
- 1-8. Racial and ethnic representation in health professions
- 1-9. Hospitalization for ambulatory-care-sensitive conditions
- 1-14. Special needs of children
- 1-15. Long-term care services

## **7. Educational and Community-Based Programs**

- 7-2. School health education
- 7-4. School nurse-to-student ratio
- 7-5. Worksite health promotion programs
- 7-6. Participation in employer-sponsored health promotion activities
- 7-7. Patient and family education
- 7-8. Satisfaction with patient education
- 7-9. Health care organization sponsorship of community health promotion activities
- 7-10. Community health promotion programs
- 7-11. Culturally appropriate community health promotion programs
- 7-12. Older adult participation in community health promotion activities

## **8. Environmental Health**

- 8-5. Safe drinking water
- 8-6. Waterborne disease outbreaks
- 8-29. Global burden of disease
- 8-30. Water quality in the U.S.-Mexico border region

## **10. Food Safety**

- 10-1. Foodborne infections
- 10-2. Outbreaks of foodborne infections
- 10-3. Antimicrobial resistance of *Salmonella* species
- 10-5. Consumer food safety practices
- 10-6. Safe food preparation practices in retail establishments

## **11. Health Communication**

- 11-1. Households with Internet access
- 11-2. Health literacy
- 11-3. Research and evaluation of communication programs
- 11-4. Quality of Internet health information sources
- 11-5. Centers for excellence
- 11-6. Satisfaction with providers' communication skills

## **13. HIV**

- 13-9. HIV/AIDS, STD, and TB education in State prisons
- 13-11. HIV testing in TB patients
- 13-12. Screening for STDs and immunization for hepatitis B

## **16. Maternal, Infant, and Child Health**

- 16-22. Medical home for children with special health care needs

## **23. Public Health Infrastructure**

- 23-1. Public health employee access to Internet
- 23-2. Public access to information and surveillance data
- 23-3. Use of geocoding in health data systems
- 23-4. Data for population groups
- 23-5. Data for Leading Health Indicators, Health Status Indicators, and Priority Data Needs at State, Tribal, and local levels
- 23-6. National tracking of Healthy People 2010 objectives
- 23-7. Timely release of data on objectives
- 23-8. Competencies for public health workers

- 23-9. Training in essential public health services
- 23-10. Continuing education and training by public health agencies
- 23-11. Performance standards for essential public health services
- 23-12. Health improvement plans
- 23-13. Access to epidemiology services
- 23-14. Model statutes related to essential public health services
- 23-16. Conducting and collaborating in prevention research

## 25. Sexually Transmitted Diseases

- 25-13. Hepatitis B vaccine services in STD clinics

## Terminology

---

(A list of all acronyms used in this publication appears in Appendix K.)

### **Advisory Committee on Immunization Practices**

**(ACIP):** Federally chartered advisory committee with the goals of providing advice to the CDC Director on decreasing disease through the use of vaccines and other biological products and on improving the safety of their use.

**Common cold:** Defined based on International Classification of Disease (ICD)-9 diagnostic codes 460.0, 461.0, 465.0, 465.8, 465.9, 472.0.

**Complete curative therapy:** Full course of recommended treatment.

**Comprehensive primary care:** All aspects of routine health care (preventive, diagnostic, and therapeutic) delivered by a trained health care provider.

**Conjugate vaccines:** A type of inactivated vaccine composed of fractions of bacteria linked to a protein. This linkage makes the vaccine more potent.

**Emerging infectious diseases:** Diseases of infectious origin whose occurrence in humans has increased within the past two decades or threatens to

increase in the near future. Recognition of an emerging disease occurs because the disease is present in the population for the first time, the disease has been detected for the first time, or links between an infectious agent and a chronic disease or syndrome have only recently been identified.

### **Group B Streptococcus**

**(GBS):** A normal germ found in the intestines and on the genitals of about one out of five pregnant women. GBS is usually not harmful to the woman carrying the germ. But it can cause dangerous infections in the blood, spinal fluid, and lungs of babies born to these women.

Early onset of group B streptococcal disease: Illness onset at less than 7 days of age.

**Invasive group B streptococcal disease:** Isolation of group B streptococcus from a normally sterile site, such as blood or cerebrospinal fluid.

**Group immunity:** The immunity of a group or community. Immunity based on the resistance to infection among a high proportion of individual members of the group.

**Hospital-acquired infection:** Any infection that a patient acquires as a result

of medical treatment while in the hospital.

**Invasive pneumococcal infection:** Isolating the bacteria *Streptococcus pneumoniae* from a normally sterile site, including blood, cerebrospinal fluid, or pleural fluid.

**Latent TB infection:** The state of being infected with the organism *Mycobacterium tuberculosis* but without signs or symptoms of active TB disease.

**Multiple sex partners:** More than one partner in the prior 6 months.

### **National Notifiable Disease Surveillance System**

**(NNDSS):** Tracking system that State health departments use to report cases of selected diseases to CDC. (See Reportable disease).

**Patient day:** A day or part of a day for which a patient was hospitalized.

**Penicillin resistant:** Having a minimum inhibitory concentration (MIC) equal to or greater than 2 µg/ml. Strains with intermediate susceptibility are not included in this category.

**Reemerging infectious diseases:** Reappearance of a known infection after a decline in occurrence. Reemergence of old infection.

tious agents can be the result of lapses in public health measures, changes in human behavior that increase person-to-person transmission of infectious agents, changes in food handling or eating habits, or changes in the way humans interact with their environment.

**Reportable disease:** A disease for which there are legal requirements for reporting and notification to public health authorities. In the United States, requirements for reporting diseases are mandated by State laws or regulations, and the list of

reportable diseases in each State differs.

**Surveillance regions:** The nine regions of the United States used for influenza surveillance purposes.

**Vaccine Adverse Events Reporting System (VAERS).** A passive surveillance system that monitors vaccine safety by collecting and analyzing reports of adverse events following immunization from vaccine manufacturers, private practitioners, State and local public health clinics, parents, and individuals who receive vaccines. CDC and the Food and Drug Administration

work together to implement VAERS.

**Vaccines:** Biological substances used to stimulate the development of antibodies and thus confer active immunity against a specific disease or number of diseases.

**Vector-borne disease:** Viral and bacterial diseases transmitted to humans by arthropods, primarily mosquitoes, ticks, and fleas.

**Zoonotic disease:** Viral and bacterial diseases transmitted to humans by arthropods, primarily mosquitoes, ticks, and fleas.

## References

1. Meltzer, M.I.; Dennis, D.T.; and Orloski, K.A. The Cost Effectiveness of Vaccinating Against Lyme Disease. *Emerging and Infectious Diseases* 5(3):321-328, May-June 1999. Retrieved December 14, 1999 <<http://www.cdc.gov/ncidod/eid/vol5no3/meltzer.htm>>.
2. Centers for Disease Control and Prevention (CDC). Summary of notifiable disease—United States, 1994. *Morbidity and Mortality Weekly Report* 43(53), 1995.
3. Rubella Surveillance National Communicable Disease Center, United States Department of Health, Education and Welfare (No. 1), June 1969.
4. Atkinson, W.; Humiston, S.G.; and Pollard, B., eds. Epidemiology and prevention of vaccine-preventable diseases. Atlanta, GA: U.S. Department of Health and Human Services, CDC, 1997.
5. Atkinson, W.L.; Orenstein, W.A.; and Krugman, S. The resurgence of measles in the United States, 1989-1990. *Annual Review of Medicine* 43:451-463, 1992.
6. Gindler, J.S.; Atkinson, W.L.; Markowitz, L.E.; and Hutchins, S.S. The epidemiology of measles in the United States in 1989-1990. *Pediatric Infectious Disease Journal* 11:841-846, 1992.
7. National Vaccine Advisory Committee. The measles epidemic: The problems, barriers and recommendations. *Journal of the American Medical Association* 266:1547-1552, 1991.
8. CDC. National Immunization Program. Atlanta, GA: CDC, Immunization Services Division, Health Services Research and Evaluation Branch, unpublished data, 1999.
9. CDC. Achievements in Public Health, 1900-1999/Impact of Vaccines Universally Recommended for Children—United States, 1990-1998. *Morbidity and Mortality Weekly Report* 48(12):243-248, 1999.
10. CDC. Notice to readers: National Vaccination Coverage Levels Among Children Aged 19 to 35 Months—United States, 1998. *Morbidity and Mortality Weekly Report* 48(37):829-830, 1999.
11. National Center for Health Statistics. *Healthy People 2000 Review, 1998-99*. Hyattsville, MD: Public Health Service, 1999, 195-205.
12. CDC. Vaccination Coverage by Race/Ethnicity and Poverty Level Among Children Aged 19 to 35 Months—United States, 1996. *Morbidity and Mortality Weekly Report* 46(41):963-968, 1997.
13. CDC. *State Immunization Requirements, 1998-1999*. Washington, DC: U.S. Government Printing Office, 1999, 1-27.
14. CDC. Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *Morbidity and Mortality Weekly Report* 48(RR-12):1-37, 1999.
15. CDC. Pneumococcal and influenza vaccination levels among adults aged >

- 65 years—United States, 1995. *Morbidity and Mortality Weekly Report* 46(39):913-919, 1997.
16. CDC. Progress towards elimination of *Haemophilus influenzae* type b disease among infants and children—United States, 1987-1995. *Morbidity and Mortality Weekly Report* 45(42):901-906, 1996.
17. Schuchat, A.; Robinson, A.K.; and Wenger, J.D. Bacterial Meningitis in the United States in 1995. *New England Journal of Medicine* 337:970-976, 1997.
18. CDC. Preventing emerging infectious disease threats: A strategy for the 21st century. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, 1998. Retrieved October 12, 1999 <<http://www.cdc.gov/ncidod/emergplan>>.
19. U.S. Department of Health and Human Services (DHHS). *Adult Immunization Action Plan, Report of the Workgroup on Adult Immunization*. Washington, DC: the Department, 1997. Retrieved November 23, 1999 <<http://www.cdc.gov/od/nvpo/adult.htm>>.
20. CDC. Reported vaccine-preventable disease—United States, 1993, and the childhood immunization initiative. *Morbidity and Mortality Weekly Report* 43(4):57-60, 1994.
21. Shefer, A.; Briss, P.; Rodewald, L.; et al. Improving immunization coverage rates: An evidence-based review of the literature. *Epidemiologic Reviews*, 21(1), 1999.
22. Hoekstra, E.J.; LeBaron, C.W.; Mega-loeconomou, Y.; et al. Impact of a large-scale immunization initiative in the special supplemental nutrition program for women, infants, and children (WIC). *Journal of the American Medical Association* 280(13):1143-1147, 1998.
23. Abramson, J.S.; O'Shea, T.M.; Ratledge, D.L.; et al. Development of a vaccine tracking system to improve the rate of age-appropriate primary immunization in children of lower socioeconomic status. *Journal of Pediatrics* 126(4):583-586, 1995.
24. CDC. Progress towards elimination of *Haemophilus influenzae* type b disease among infants and children—United States, 1987-1997. *Morbidity and Mortality Weekly Report* 47(46):993-998, 1998.
25. CDC. Summary of notifiable disease—United States 1997. *Morbidity and Mortality Weekly Report* 46(54):1-87, 1998.
26. CDC. Prevention of varicella: Recommendations of the advisory committee on immunization practices (ACIP). *Morbidity and Mortality Weekly Report* 45(RR-11):1-36, 1996.
27. CDC. National, State and urban area vaccination coverage levels among children aged 19-35 months—United States, 1997. *Morbidity and Mortality Weekly Report* 47(26):547-554, 1998.
28. Rota, J.S.; Heath, J.L.; Rota, R.A.; et al. Molecular epidemiology of measles virus: Identification of pathways of transmission and implications for measles elimination. *Journal of Infectious Diseases* 173:32-37, 1996.
29. CDC. Measles—United States, 1996 and the interruption of indigenous transmission. *Morbidity and Mortality Weekly Report* 46(11):242-246, 1997.
30. CDC. Epidemiology of Measles—United States, 1998. *Morbidity and Mortality Weekly Report* 48(34):749-753, 1999.
31. Wharton, M. Mumps. In: Wallace, R.B.; Duebbling, B.N.; Last, J.M.; et al. (eds.). *Maxcy-Rosenau-Last. Public Health and Preventive Medicine*. 14th ed. Stamford, CT: Appleton & Lange, 1998, 93-95.
32. CDC. Measles, mumps and rubella—vaccine use and strategies for elimination of measles, rubella—and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *Morbidity and Mortality Weekly Report* 47(RR-8):1-57, 1998.
33. CDC. Rubella and congenital rubella syndrome—United States, 1994-1997. *Morbidity and Mortality Weekly Report* 46(16):350-354, 1997.
34. Bisgard, K.M.; Hardy, I.R.B.; Popovic, T.; et al. Respiratory diphtheria in the United States, 1980-1995. *American Journal of Public Health* 88:787-791, 1998.
35. CDC. Toxigenic *Corynebacterium diphtheriae*—Northern Plains Indian Community, August-October 1996. *Morbidity and Mortality Weekly Report* 46(22):506-510, 1997.
36. Bardenheier, B.; Prevots, D.R.; Khetsuriani, N.; et al. Tetanus—United States, 1995-1997. *Morbidity and Mortality Weekly Report* 47(SS-2):1-13, 1998.
37. CDC. Pertussis vaccination: Use of acellular pertussis vaccines among infants and young children. *Morbidity and Mortality Weekly Report* 46(RR-7):1-25, 1997.
38. Guris, D.; Strebel, P.M.; Tachdjian, R.; et al. Effect-

- tiveness of the pertussis vaccination program as determined by use of the screening method—United States, 1992-1994. *Journal of Infectious Diseases* 176:456-463, 1997.
39. Bisgard, K.M.; Kao, A.; Leake, J.; et al. The epidemiology of *Haemophilus influenzae* invasive disease in the United States, 1994-1995: Near disappearance of a child vaccine preventable disease. *Emerging Infectious Diseases* 4(2):229-237, 1998.
40. CDC. Varicella-related deaths among adults—United States, 1997. *Morbidity and Mortality Weekly Report* 46(19):409-412, 1997.
41. CDC. *Hepatitis Surveillance Report*, No. 56. Atlanta, GA: Centers for Disease Control and Prevention, 1996.
42. CDC. Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP). *Morbidity and Mortality Weekly Report* 40(RR-13):1-19, 1991.
43. CDC. Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. *Morbidity and Mortality Weekly Report* 47(RR-19):1-39, 1998.
44. CDC. A strategic plan for the elimination of tuberculosis in the United States. *Morbidity and Mortality Weekly Report* 38(S-3):1-25, 1989.
45. American Thoracic Society/CDC. Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children. *American Journal of Respiratory Care Medicine* 149:1359-1374, 1994.
46. CDC. Screening for tuberculosis and tuberculosis infection in high-risk populations. *Morbidity and Mortality Weekly Report*, 44 (RR-11):9-13, 1995.
47. Marshall, B., and Warren, J.R. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet* 1:1273-1275, 1983.
48. CDC. Knowledge about causes of peptic ulcer disease—United States. *Morbidity and Mortality Weekly Report* 45(42):985-987, 1997.
49. American Digestive Health Foundation and Opinion Research Corporation. Familiarity with *H. pylori* among adults with digestive disorders and their views toward diagnostic and treatment options. Bethesda, MD: American Digestive Health Foundation and Opinion Research Corporation, 1995.
50. Breuer, T.; Malaty, H.M.; Goodman, K.; et al. Has the scientific evidence about *Helicobacter pylori* infection in gastrointestinal diseases reached the practicing physicians in the U.S.? *American Journal of Gastroenterology* 91:1905, 1996.
51. CDC. National Center for Infectious Diseases, Division of Bacterial and Mycotic Diseases, Atlanta, GA, 1999.
52. Powell, S.E.; Marcy, S.M.; Phillips, W.R.; et al. Otitis Media—principles of Judicious Use of Antimicrobial Agents. *Pediatrics* 101:165-171, 1998.
53. Redd, S.C.; Markowitz, L.E.; and Katz, S.L. Measles Vaccine. In: Plotkin, S.A. and Orenstein, W.A. (eds.). *Vaccines*. 3rd ed. Philadelphia, PA: W.B. Saunders Company, 1999, 222-226.
54. Orenstein, W.H.; Hinman, A.R.; and Rodewald, L.E. Public Health Considerations in the United States. In: Plotkin, S.A. and Orenstein, W.A. (eds.). *Vaccines*. 3rd ed. Philadelphia, PA: W.B. Saunders Company, 1999, 1006-1032.
55. Dowdle, W.R.; Hopkins, D.R., eds. The Eradication of Infectious Diseases. Dahlem Workshop Report. Chichester, NY: John Wiley and Sons, 1997, 1-218.
56. CDC. School Immunization Requirements for Measles—United States, 1981. *Morbidity and Mortality Weekly Report* 30:158-160, 1981.
57. CDC. Notice to readers: Recommended childhood immunization schedule—United States, 1999. *Morbidity and Mortality Weekly Report* 48(1):8-16, 1999.
58. CDC, National Immunization Program, Immunization Services Division. Annual Immunization Assessment Progress—Percentage of Sites Assessed Nationwide in 1997 [chart]. Atlanta, GA: the Center, 1997. Retrieved November 23, 1999 <<http://www.cdc.gov/nip/afix/pres/prog/97perc.gif>>.
59. Watt, J.; Kahane, S.; Smith, N.; et al. The difference between measured and estimated vaccination coverage among private physicians in California. Presented before the Ambulatory Pediatric Association in New Orleans, LA, May 1998.
60. LeBaron, C.W.; Chaney, M.; Baughman, A.L., et al. Impact of measurement and feedback on vaccination coverage in public clinics, 1988-1994. *Journal of the American Medical Association* 277:631-635, 1997.
61. Dini, E.F.; Chaney, M.; Moolenaar, R.L.; et al. Information as intervention: How

- Georgia used vaccination coverage data to double public sector vaccination coverage in seven years. *Journal of Public Health Management Practice* 2(1):45-49, 1996.
62. National Committee for Quality Assurance. The Health Plan Employer Data and Information Set (HEDIS) 3.0/1998, Vol. 2, Technical Specifications. Washington, DC: the Committee, 1997, 38-48.
63. Advisory Committee on Immunization Practices, CDC. Programmatic strategies to increase vaccination rates—assessment and feedback of provider-based vaccination coverage information. *Morbidity and Mortality Weekly Report* 45(10):219-220, 1996.
64. CDC. *Standards for Pediatric Immunization Practices*. Washington, DC: U.S. Government Printing Office, 1993.
65. CDC. National Immunization Program. Atlanta, GA: CDC, Data Management Division, Systems Development Branch, unpublished data, 1999.
66. Sharp, K.; Edgar, T.; and Fowler, K. Findings of Focus Group Research on Immunization Registries. Rockville, MD: Westat, December 1998. Retrieved October 1999 <[http://www.cdc.gov/nip/registry/i\\_fgmenu.htm](http://www.cdc.gov/nip/registry/i_fgmenu.htm)>.
67. CDC. Immunization of Adolescents: Recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. *Morbidity and Mortality Weekly Report* 45(RR-13):1-16, 1996.
68. Benson, V., and Marano, M.A. Current estimates from the National Health Interview Survey, 1995. National Center for Health Statistics. *Vital Health Statistics* 10(199). 1998.
69. National Center for Health Statistics. *Health—United States, 1994*. Hyattsville, MD: Public Health Service. 1995.
70. Unti, L., and Woodruff, B.A. A review of adolescent school-based hepatitis B vaccination projects: A report prepared for the Centers for Disease Control and Prevention, Hepatitis Branch. Washington, DC: U.S. Department of Health and Human Services, Public Health Service, October 1996.
71. Fedson, D.S. Adult immunization: Summary of the National Vaccine Advisory Committee report. *Journal of the American Medical Association* 272:1133, 1994.
72. CDC. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *Morbidity and Mortality Weekly Report* 47(RR-6):1-26, 1998.
73. CDC. Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices. *Morbidity and Mortality Weekly Report* 46(RR-8):1-24, 1997.
74. Gyorkos, T.W.; Tanenbaum, T.N.; Abrahamowicz, M.; et al. Evaluation of the effectiveness of immunization delivery methods. *Canadian Journal of Public Health* 85:S14-S30, 1994.
75. Agency for Health Care Policy and Research. *Implementing preventive care*. Retrieved January 6, 1999 <<http://www.ahcpr.gov/ppip/handbkiv.htm>>.
76. CDC. Notice to Readers: Recommendations of the Advisory Committee on Immunization Practices: Revised Recommendations for Routine Poliomyelitis Vaccination. *Morbidity and Mortality Weekly Report* 48(27):590, 1999.
77. Cody, C.L.; Baraff, L.J.; Cherry, J.D.; et al. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. *Pediatrics* 68:650-660, 1981.
78. CDC. Diphtheria, tetanus, and pertussis: Recommendations for vaccine use and other preventive measures. Recommendations of the Advisory Committee on Immunization Practices. *Morbidity and Mortality Weekly Report* 40(RR-10):1-28, 1991.
79. Stratton, K.R.; Howe, C.J.; and Johnston, Jr., R.B. *Adverse Events Associated with Childhood Vaccines—Evidence Bearing on Causality*. Washington, DC: National Academy Press, 1994.
80. Howson, C.P.; Howe, C.J.; and Fineberg, F.V. *Adverse Effects of Pertussis and Rubella Vaccines*. Washington, DC: National Academy Press, 1991.
81. Chen, R.T.; Glasser, J.W.; Rhodes, P.H.; et al. The Vaccine Safety Datalink Project: A new tool for improving vaccine safety monitoring in the United States. *Pediatrics* 99:765-773, 1997.